Neuronetics, INC

Neuronetics, Inc. announced changes to its principal financial and accounting officer roles, with Nir Naor assuming the position and Francis X. Brown III transitioning to a consultant.

Neuronetics, Inc. announced its second quarter 2026 financial and operating results, highlighting a 9.1% increase in total revenue and a significant reduction in net loss.

Neuronetics appoints Nir Naor as CFO, promotes Cory Anderson, and announces Andrew Macan's departure.

Neuronetics, Inc. successfully concluded its 2026 Annual Meeting, confirming director elections and the approval of a new equity incentive plan.

Neuronetics, Inc. has amended its consulting agreement with Francis X. Brown III to clarify his ongoing role as Interim Principal Financial and Accounting Officer.

Neuronetics announced its first quarter 2026 financial results, reporting an 8% increase in total revenue to $34.5 million, driven by strong U.S. clinic revenue growth.

Neuronetics reported increased revenue in Q2 2026 driven by its Greenbrook segment, but faces substantial doubt regarding its ability to continue as a going concern due to projected covenant non-compliance.

Neuronetics reports an 8% increase in Q1 2026 revenue to $34.5 million, driven by clinic services, but faces substantial doubt about its ability to continue as a going concern due to projected covenant breaches.

Neuronetics, Inc. reported a significant revenue increase in Q3 2025, primarily driven by the Greenbrook TMS acquisition, despite continued operating losses and gross margin compression.

Neuronetics reported a significant revenue increase in Q2 2025, primarily driven by the Greenbrook acquisition, though net losses persisted and gross margins declined.

Neuronetics' Q1 2025 revenue increased by 84% year-over-year, driven by the acquisition of Greenbrook, though net losses also widened.

Neuronetics' Q3 2024 results show a slight revenue increase year-over-year, alongside a strategic reorganization aimed at improving operational efficiency.

Neuronetics, Inc. announced significant revenue growth for 2025, driven by the Greenbrook acquisition, alongside a new CEO appointment and ongoing efforts to improve profitability.

Neuronetics' 2024 10-K filing reveals a year of strategic shifts, including the acquisition of Greenbrook, aimed at expanding mental health treatment access.

Neuronetics' annual 10-K filing shows a 9% increase in revenue to $71.3 million for 2023, alongside a net loss of $30.2 million.

Jorey Chernett, a 10% owner of Neuronetics, Inc., reported multiple transactions in common stock on August 13, 2026.

Jorey Chernett, a 10% owner of Neuronetics, Inc., purchased 35,000 shares of common stock on July 14, 2026 for $1.78 per share.

Director Avinash Amin transferred shares of Neuronetics, Inc. common stock to affiliated Madryn Health Partners funds as part of director compensation.

Madryn Asset Management, LP and affiliated entities have reported changes in their beneficial ownership of Neuronetics, Inc. common stock.

Director Megan Rosengarten was granted 30,000 restricted stock units by Neuronetics, Inc. as part of an equity award.

Director Glenn P. Muir was granted 30,000 restricted stock units by Neuronetics, Inc. on May 28, 2026.

Neuronetics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, executive compensation, and an equity incentive plan.

Neuronetics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Neuronetics, Inc. is holding its annual virtual stockholder meeting on May 22, 2025, to vote on key proposals including director elections, auditor ratification, executive compensation, and amendments to corporate governance documents.

Neuronetics, Inc. amended its Registration Rights Agreement with the Madryn Parties, extending the Demand Registration Period from 180 to 365 days following the consummation of the Arrangement.

Neuronetics, Inc. has engaged D.F. King & Co., Inc. to assist in soliciting proxies for its Special Meeting of Stockholders to be held on November 8, 2024.

Neuronetics and Greenbrook TMS have received an interim order from the Ontario Superior Court of Justice for their proposed all-stock transaction, with shareholder meetings scheduled for November 8, 2024.

Neuronetics, Inc. and major shareholder Jorey Chernett have established a framework for board alignment, including Chernett's opportunity to recommend a new board member.

Jorey Chernett has filed an amendment to Schedule 13D, reporting increased beneficial ownership of Neuronetics, Inc. common stock to 15.17%.

Jorey Chernett, a significant shareholder in Neuronetics, Inc., has formally requested a comprehensive review of strategic alternatives, including a potential sale of the company's TMS business.

Jorey Chernett has filed a Schedule 13D, disclosing a 14.12% beneficial ownership in Neuronetics, Inc., citing the shares as an undervalued investment opportunity.

Madryn Asset Management and its affiliates updated their Schedule 13D filing for Neuronetics, Inc., disclosing a 30.3% beneficial ownership and new terms for registration rights and voting agreements.

Madryn Asset Management and its affiliates have reduced their aggregate beneficial ownership in Neuronetics, Inc. to 31.4% after selling over 3.5 million shares.

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly filed to report beneficial ownership of 5.0% of Neuronetics, Inc. common stock.

Jorey Chernett has reported a beneficial ownership of 10.85% of Neuronetics, Inc.'s common stock as of March 17, 2026.

Parian Ultreia LP has reported a 7.0% beneficial ownership stake in Neuronetics, Inc., holding 4,844,908 shares with sole voting and dispositive power.

Jorey Chernett has reported an amended beneficial ownership of 9.97% in Neuronetics, Inc., holding 6,827,031 common shares.

Jorey Chernett has reported a 6.4% beneficial ownership stake in Neuronetics, Inc., holding 4,403,498 common shares as a passive investor.

Kent Lake PR LLC, Kent Lake Partners LP, and Benjamin Natter have filed an amended Schedule 13G, indicating they no longer hold any beneficial ownership in Neuronetics, Inc. as of December 31, 2024.